We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
Atenolol or propranolol in hypertensive patients poorly controlled on captopril and frusemide.
Eighteen patients whose clinic blood pressure ( BP ) remained over 95 mmHg despite treatment with captopril 50 mg twice daily plus frusemide 40 mg twice daily were r and omised in a crossover study to four weeks ' treatment with once daily atenolol 100 mg , slow release propranolol 160 mg or placebo . The reduction in BP on atenolol was superior to that on both propranolol and placebo . The mean supine BP 24 hours post dosing were 177/110 mmHg ( placebo ) , 173/109 mmHg ( propranolol ) and 164/100 mmHg ( atenolol ) . The corresponding mean heart rates were 77 bpm ( placebo ) , 63 bpm ( propranolol ) and 62 bpm ( propranolol ) and 62 bpm ( atenolol ) . The difference in hypotensive efficacy between atenolol and propranolol is not readily explained but our study shows that atenolol has a clinical ly useful supplementary effect on BP . Refractory hypertension remains an important clinical problem and further studies are required to establish the optimum combination of drugs that should be used with captopril in order to achieve ' target ' BP in patients with moderate to severe hypertension
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .